---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-23-000030"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:10:40.906897+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trend Innovations names new CEO Kenneth Waggoner; ex-CEO Tunevic stays as President

## Summary
- Kenneth L. Waggoner named CEO on Apr 20, 2023, replacing Natalija Tunevic who remains President and director.
- Annual base salary of $720,000 in common stock, retroactively increased to $1,440,000 upon listing on a national exchange.
- Shares paid quarterly: $180,000 per quarter divided by 20-day VWAP; $2,500/mo health plan also paid in shares.
- Agreement term one year from April 20, 2023, auto-renewing; includes confidentiality, invention assignment, and indemnification.
- Waggoner has 45 years experience, including as CEO of PharmaCyte Biotech (2013-2022) and partner at Brobeck.

## SEC filing metadata
- accession: 0001740797-23-000030
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/tren8kceo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-23-000030
- JSON: https://secwatch.observer/filing/0001740797-23-000030.json
- Plain text: https://secwatch.observer/filing/0001740797-23-000030.txt

## Key facts
- Executive change
  Natalija Tunevic departed as President at AVAI BIO, INC..
  - Action: resigned as CEO
  - Role: President
  source text: Natalija Tunevic resigned as CEO of the Company but will continue to serve as President and a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm
- Executive change
  Kenneth L. Waggoner was appointed as Chief Executive Officer at AVAI BIO, INC..
  - Action: retained
  - Role: Chief Executive Officer
  source text: On April 20, 2023, Trend Innovations Holding Inc. (the “Company”) and Kenneth L. Waggoner entered into an Executive Compensation Agreement pursuant to which Mr. Waggoner was retained as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000030/0001740797-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.